{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-23-000027","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.350672+00:00","generated_at":"2026-06-19T02:29:02.428337+00:00","sec_items":["1.01","1.02","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Skye Bioscience enters master transaction agreement with major shareholder to convert debt and exercise warrants","bullets":["Emerald Health Sciences exercised 16,641,486 warrants for $282,905, paid by reducing Skye's debt under the Credit Agreement.","Remaining debt of $1,597,236 converted into 41,379,164 shares of common stock at $0.0386 per share.","Credit Agreement terminated in full after the conversion and warrant exercise.","Emerald Health Sciences agreed to use best efforts to distribute its Skye shares to its shareholders pro-rata upon a national exchange listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-23-000027","json":"https://secwatch.observer/filing/0001516551-23-000027.json","markdown":"https://secwatch.observer/filing/0001516551-23-000027.md","text":"https://secwatch.observer/filing/0001516551-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000027/0001516551-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000027/skye-20230216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:29:02.428337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08006c177c5b2739587069b896987631d555f821","claim":"Skye Bioscience, Inc. entered into Master Transaction Agreement with Emerald Health Sciences, Inc. valued at Exercise of 16,641,486 warrants at aggregate exercise price of $282,905 paid via reduction in debt; (effective 2023-02-16).","evidence_excerpt":"Item 1.01 Entry into a Material Definitive Agreement. Effective February 16, 2023, Skye Bioscience, Inc. (the \" Company \") and Emerald Health Sciences, Inc. (\" Sciences \") entered into a master transaction agreement (the \" MTA \").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000027/0001516551-23-000027-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Emerald Health Sciences, Inc."},{"label":"Value","value":"Exercise of 16,641,486 warrants at aggregate exercise price of $282,905 paid via reduction in debt;"},{"label":"Effective","value":"2023-02-16"}],"fact_type":"material_agreement"},{"claim_id":"8a38b90bf9629bcb676bdb9b11be548abdef3441","claim":"Skye Bioscience, Inc. terminated Amended and Restated Multi-Draw Credit Agreement with Emerald Health Sciences, Inc. valued at Terminated in its entirety per the terms of the MTA following conversion of remaining balance (effective 2023-02-22).","evidence_excerpt":"Following the issuance of shares described above, the Credit Agreement was terminated in its entirety per the terms of the MTA.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000027/0001516551-23-000027-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Emerald Health Sciences, Inc."},{"label":"Value","value":"Terminated in its entirety per the terms of the MTA following conversion of remaining balance"},{"label":"Effective","value":"2023-02-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}